Final Height in Estrogen-Treated Patients with Turner Syndrome

Demetriou, Efstratios; Sj, Emans; Jf, Crigler

doi:10.1097/00006254-198505000-00014

Cited by 12 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6, the results from 8 available studies on estrogen effects in patients with gonadal dysgenesis are compiled (119,121,123,124,(142)(143)(144)(145). The data are plotted in relation to bone age at onset of estrogen therapy, which is variable over a range of 6 yr between 8.1 yr (145) and 13.8 yr (143). In all these studies, bone ages were rated according to Greulich and Pyle (137) except for patients starting treatment at 13.0 yr of bone age in whom calculations were made according to the method of Tanner et al (138).…”

Section: A Role Of Estrogensmentioning

confidence: 99%

“…In order to include the patients studied by Ross et al (123), mean bone age was arbitrarily considered to be delayed 1.5 yr below their mean chronological age, based on the findings of Martinez et al (124). While weight was not stated by the authors, body weight-related doses of estrogen were calculated for a 40kg patient (119,(141)(142)(143)145). The following drug equivalents were used in this compilation: 10 /u,g/day ethinylestradiol (EE) = 1 mg/day 17/3-estradiol (given orally) = 2 mg/month of long-acting estradiol ester (given im) = 0.3 mg/day conjugated estrogens (given orally).…”

Section: A Role Of Estrogensmentioning

confidence: 99%

See 1 more Smart Citation

Linear Growth as a Function of Age at Onset of Puberty and Sex Steroid Dosage: Therapeutic Implications*

Bourguignon

1988

Endocrine Reviews

155

View full text Add to dashboard Cite

show abstract

Section: A Role Of Estrogensmentioning

confidence: 99%

Section: A Role Of Estrogensmentioning

confidence: 99%

Linear Growth as a Function of Age at Onset of Puberty and Sex Steroid Dosage: Therapeutic Implications*

Bourguignon

1988

Endocrine Reviews

155

View full text Add to dashboard Cite

show abstract

“…One of the crucial issues is the tim ing of the induction of puberty. Oestrogens per se, either endogenous through spontaneous puberty [5,12] or dur ing induction of puberty [3][4][5]. do not seem to compro mise final height.…”

Section: Discussionmentioning

confidence: 99%

“…but at an earlier and more physiological age [3][4][5], Opin ions conflict as to the possible beneficial effects of treat ment with anabolic steroids on final height [6][7][8]. More over.…”

Section: Introductionmentioning

confidence: 99%

Results of Two Years of Growth Hormone Treatment Followed by Combined Growth Hormone and Oestradiol in Turner Syndrome

Knudtzon

Aarskog²

1993

Horm Res

View full text Add to dashboard Cite

The effects of treatment with human growth hormone (GH) for 2 years, followed by combined treatment with GH and oestradiol valerate, were studied in girls with Turner syndrome, aged 7.0-16.6 years. Height SDS (Turner standards) increased after GH treatment, and height velocity SDS (Turner standards) increased dramatically 6 months after the start of GH treatment and gradually declined after 2 years’ treatment. A further increase occurred after 18 months of GH and oestradiol treatment in conjunction with the pubertal growth spurt, followed by a decline 6 months later. Height SDS for bone age increased during GH treatment, and remained virtually unchanged after the introduction of oestradiol. Predicted final height increased after the first year of GH treatment only. The use of GH and oestrogen treatment in Turner syndrome is discussed in the light of these preliminary results.

show abstract

“…In this case, there was no difference in the inci- [26] 1982 142.6 Ranke et al [21] 1983 146.8 Ranke et al [27] 1991 146.9 Park et al [28] 1983 142(7.6). oestrogen Demetriou et al [29] 1984 142.6 (4.8), oestrogen Sybert [30] 1984 146.9(4.9) 147.9 (5.0). androgen Takano et al [31] 1988 136.4-137.5 141.9. androgen/ocstrogen 131.6, androgen (spontaneous puberty) dence or prevalence of calciuria between blinded groups.…”

Section: Randomized Placebo-controlled Trials To Final Heightmentioning

confidence: 99%

Study Design for Final Height Determination in Turner Syndrome: Pros and Cons

Chipman¹

1993

Horm Res

View full text Add to dashboard Cite

Early studies on the use of human growth hormone (hGH) for the treatment of Turner syndrome are reviewed and attention is drawn to the higher dose used compared with the doses for growth hormone deficiency (GHD). Patients with Turner syndrome responded less consistently than GHD patients to hGH. The prediction of final height in Turner syndrome from bone age is uncertain – long-term trials are essential to resolve final height questions. The pros and cons of randomized placebo-controlled trials, randomized nontreatment-controlled trials and historical controlled trials are compared, and it is concluded that in the USA, a randomized placebo-controlled trial is the most appropriate study design. The ethical considerations of such a long-term trial, in terms of risk vs. benefit, and the need for a placebo-treated group are also discussed.

show abstract

Final Height in Estrogen-Treated Patients with Turner Syndrome

Cited by 12 publications

References 0 publications

Linear Growth as a Function of Age at Onset of Puberty and Sex Steroid Dosage: Therapeutic Implications*

Linear Growth as a Function of Age at Onset of Puberty and Sex Steroid Dosage: Therapeutic Implications*

Results of Two Years of Growth Hormone Treatment Followed by Combined Growth Hormone and Oestradiol in Turner Syndrome

Study Design for Final Height Determination in Turner Syndrome: Pros and Cons

Contact Info

Product

Resources

About